Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of Inhaled Nezulcitinib (TD-0903) Administered in the Setting of Supplemental Oxygenation Scenarios in Healthy Participants

NCT05091723 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT05091723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05091723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of Inhaled Nezulcitinib (TD-0903) Administered in the Setting of Supplemental Oxygenation Scenarios in Healthy Participants
Lead sponsor
Theravance Biopharma
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2021
Completion date
November 24, 2021
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury (ali) due to coronavirus disease-2019 (covid-19)